Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
Want to see MAZE full AI Analyst Report?
MAZE Stock Chart & Stats
$26.85
--
Market closed
$26.85
--
Day’s Range― - ―
52-Week Range$7.16 - $53.65
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.07M
Market Cap
$1.33B
Enterprise Value$1.17B
Total Cash (Recent Filing)$341.92M
Total Debt (Recent Filing)$23.31M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
May 20, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding49,708,656
10 Day Avg. Volume867,710
30 Day Avg. Volume1,074,617
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-15.79
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.02K
Enterprise Value/Ebitda-8.67
Forecast
1Y Price Target
$64.45Price Target Upside140.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.84
Revenue Forecast (FY)$10.00M
Bulls Say, Bears Say
Bulls Say
Biomarker And Trial DesignA multi-marker biomarker approach—including TNFR1 and TNFR2 and early kidney injury markers—improves risk prediction and could enable enriched trial endpoints beyond urine albumin-to-creatinine ratio to better detect drug effects.
Clinical Efficacy In APOL1-mediated DiseasePhase II results showed meaningful reductions in urine protein in APOL1-mediated kidney disease, with especially strong responses in focal segmental glomerulosclerosis and in non-diabetic cohorts, suggesting potential best-in-class activity.
Mechanism Of ActionMechanistic studies indicate that selective inhibition of the SLC6A19 transporter protects proximal tubule cells from toxin-induced damage, supporting a clear kidney-protecting mode of action for the program.
Bears Say
Development Pathway And Near-term RiskUnclear pivotal development plans and dependence on an upcoming Phase II readout as a binary catalyst increase the risk of material downside if follow-up data do not confirm early signals.
Efficacy In Diabetic PatientsThe diabetic cohort produced modest and inconsistent responses and included patients with increased proteinuria, leaving uncertainty about the class's effectiveness in the diabetes population.
Sample Size And GeneralizabilitySmall patient numbers and heavy reliance on subgroup signals limit confidence in the durability and generalizability of efficacy findings, creating a need for larger controlled studies to validate results.
Maze Therapeutics, Inc. News
MAZE FAQ
What was Maze Therapeutics, Inc.’s price range in the past 12 months?
Maze Therapeutics, Inc. lowest stock price was $7.16 and its highest was $53.65 in the past 12 months.
What is Maze Therapeutics, Inc.’s market cap?
Maze Therapeutics, Inc.’s market cap is $1.33B.
When is Maze Therapeutics, Inc.’s upcoming earnings report date?
Maze Therapeutics, Inc.’s upcoming earnings report date is May 20, 2026 which is in 34 days.
How were Maze Therapeutics, Inc.’s earnings last quarter?
Maze Therapeutics, Inc. released its earnings results on Apr 06, 2026. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.714 by $0.064.
Is Maze Therapeutics, Inc. overvalued?
According to Wall Street analysts Maze Therapeutics, Inc.’s price is currently Undervalued.
Does Maze Therapeutics, Inc. pay dividends?
Maze Therapeutics, Inc. does not currently pay dividends.
What is Maze Therapeutics, Inc.’s EPS estimate?
Maze Therapeutics, Inc.’s EPS estimate is -0.58.
How many shares outstanding does Maze Therapeutics, Inc. have?
Maze Therapeutics, Inc. has 49,708,656 shares outstanding.
What happened to Maze Therapeutics, Inc.’s price movement after its last earnings report?
Maze Therapeutics, Inc. reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.714. Following the earnings report the stock price went up 1.01%.
Which hedge fund is a major shareholder of Maze Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MAZE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Maze Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.45 (140.05% Upside)
$64.45 (140.05% Upside)
Blogger Sentiment
Bullish
MAZE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 19.4%
Last 30 Days ▲ 46.5%
Last 30 Days ▲ 46.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
225.64%
12-Months-Change
Fundamentals
Return on Equity
-40.70%
Trailing 12-Months
Asset Growth
65.10%
Trailing 12-Months
Company Description
Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
MAZE Stock 12 Month Forecast
Average Price Target
$64.45
▲(140.05% Upside)
Technical Analysis
Ownership Overview
12.09% Insiders
6.22% Mutual Funds
70.58% Other Institutional Investors
4.81% Public Companies and
Individual Investors